BURLINGTON, Mass. , July 22,2014 /PRNewswire/ --Decision Resources Group finds that over half of audited multiple sclerosis (MS) patients currently treated with Biogen Idec's oral disease-modify therapy (DMT) Tecfidera have ever experienced flushing ... OSIX News, 1 month ago
The Launch of Five Immunomodulatory Therapies for Relapsing Forms of Multiple Sclerosis Will Contribute to 4 Percent Annual Growth of the Total Market from 2013 to 2023 - PharmiWeb, 3 weeks ago
New Biogen MS drug challenges Copaxone - Globes, 1 week ago
1 images for "Tecfidera Treated Patients"
Tecfidera (dimethyl fumarate) should be available for people with relapsing remitting MS in England and Wales, the National Institute for Health and Care Excellence (NICE) has announced. The NHS must now begin funding this treatment for eligible ...Multiple Sclerosis Society, 6 days ago MS pill Tecfidera available on NHS in England and Wales Noodls, 1 month ago
News Categories Clinical Trials Research News Industry Trends AgencyPharmscope, 1 month ago
MISSISSAUGA, ON, Aug. 7, 2014 /CNW/ -Biogen Idec Canada announces today that Alberta Health will now reimburse TECFIDERA (dimethyl fumarate) through the Alberta Drug Benefit List (DBL). TECFIDERA is a first-line oral treatment for adults with ...MoneyShow.com, 3 weeks ago TECFIDERA(tm), a First-Line Oral Treatment for Multiple Sclerosis, Reimbursed Finwin, 3 weeks ago
[description]Many ACA plans have closed drug formularies that exclude some drugs to treat chronic diseases, saddling patients with the full cost of these medications.[/description ] An estimated eight million people have signed up for health care ...World Socialist Web Site, 1 month ago
Federal regulators Tuesday okayed for US sale a Genzyme experimental capsule that could become the top-selling pill to treat the rare genetic disorder Gaucher disease. Food and Drug Administration approval of the drug candidate, called Cerdelga, ...Boston Globe, 1 week ago
Scrambling to stay ahead of the competition in bringing multiple sclerosis drugs to market, Biogen Idec Inc. won US regulatory approval Friday to sell a new type of injectable drug that treats adults with the most common form of the ...Boston Globe, 2 weeks ago Company Update: Biogen Idec Inc (NASDAQ:BIIB) Donald Johns Joins Biogen Idec to Lead ALS Innovation Hub Jutia Group, 1 week ago Biogen Idec finally gets approval for MS drug Plegridy Examiner.com, 2 weeks ago Market Update: Biogen Idec Inc (NASDAQ:BIIB) Biogen wins U.S. approval of long acting multiple sclerosis drug Jutia Group, 2 weeks ago
More from: , M&A Portal...and 2 other sources
Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Revision: 1, Authorised
This is a summary of the European public assessment report (EPAR) for Tecfidera. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on ...European Medicines Agency, 3 weeks ago
It's hard to imagine that Biogen Idec (NASDAQ: BIIB Tecfidera was the third oral MS drug to get the FDA green-light when it was approved in March 2013, but while Novartis (NYSE: NVS Another great quarter Biogen's second quarter sales jumped 40% ...Motley Fool, 1 month ago NICE Gives Nod to Biogen Idec's MS Drug Tecfidera FDA News, 1 month ago US FDA approves Biogen's MS drug Bio Spectrum Asia, 1 week ago
In final guidance, the National Institute for Health and Care Excellence (NICE) has recommended the use of Biogen Idec's multiple sclerosis drug, dimethyl fumarate (also called Tecfidera). The NHS now has a legal obligation to begin funding ...FirstWord Pharma, 5 days ago NICE issues positive draft FAD guidance on Tecfidera11-07-2014 Pharma Letter, 1 month ago
on your WebpageAdd Widget >Get your members hooked!